Abstract
Side chain topography of amino acids that are part of a peptide’s pharmacophore represents a crucial structural feature in peptidomimetic design. Constraining the side chain dihedral angles (χ angles) may limit the number of low energy conformations and lead to more potent, receptor subtype selective and enzymatically stable peptide ligands. The current chapter describes this strategy for aromatic amino acids such as Phe, Tyr, Trp, and His. The side chains of these residues are incorporated in or mimicked by amino-arylazepinones. A selection of synthetic pathways that were used and developed by our laboratory is described for obtaining conformationally constrained 4-amino-(7-hydroxy)-2-benzazepinones [Aba (or Hba)] and the corresponding amino-indolo- and amino-triazoloazepinones (Aia and Ata, respectively). These azepinone mimics were synthesized from amino acid educts and have been used in various biological applications. Moreover, other heterocyclic amino-azepinones were prepared based on ring-closing metathesis and post-cyclization modifications. Further elaboration of the substitution patterns in these azepinones has rendered them highly versatile building blocks for use in peptidomimetic design. The selected biological applications illustrate their potential for the development of novel peptide-based pharmacological probes and drug candidates.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kessler H (1982) Conformation and biological activity of cyclic peptides. Angew Chem Int Ed 21(7):512–523
Kazmierski W, Hruby VJ (1988) A new approach to receptor ligand design: synthesis and conformation of a new class of potent and highly selective μ opioid antagonists utilizing tetrahydroisoquinoline carboxylic acid. Tetrahedron 44(3):697–710
Bryant SD, Jinsmaa Y, Salvadori S et al (2003) Dmt and opioid peptides: a potent alliance. Biopolymers 71(2):86–102
Tourwe D, Verschueren K, Frycia A et al (1996) Conformational restriction of Tyr and Phe side-chain in opioid peptides: information about preferred and bioactive side-chain topology. Biopolymers 38:1–12
Wu H, Wacker D, Mileni M et al (2012) Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485(7398):327–332
Schiller PW, Nguyen TM, Weltrowska G et al (1992) Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. Proc Natl Acad Sci 89(24):11871–11875
Freidinger RM, Veber DF, Perlow DS et al (1980) Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog. Science 210(4470):656–658
Perdih A, Kikelj D (2006) The application of Freidinger lactams and their analogs in the design of conformationally constrained peptidomimetics. Curr Med Chem 13(13):1525–1556
Flynn GA, Beight DW (1989) Novel antihypertensive agent. European Patent 0249224
de Laszlo SE, Bush BL, Doyle JJ et al (1992) Synthesis and use of 3-amino-4-phenyl-2-piperidones and 4-amino-2-benzazepin-3-ones as conformationally restricted phenylalanine isosteres in renin inhibitors. J Med Chem 35(5):833–846
Casimir JR, Guichard G, Briand J-P (2002) Methyl 2-((succinimidooxy)carbonyl)benzoate (MSB): a new, efficient reagent for N-phthaloylation of amino acid and peptide derivatives. J Org Chem 67(11):3764–3768
Ilisz I, Ballet S, Van Rompaey K et al (2007) High-performance liquid chromatographic separation of stereoisomers of N-phthaloyl-protected amino acids and dipeptidomimetics. J Sep Sci 30(12):1881–1887
Severino B, Fiorino F, Esposito A et al (2009) Efficient microwave-assisted synthesis of 4-amino-2-benzazepin-3-ones as conformationally restricted dipeptide mimetics. Tetrahedron 65(1):206–211
Ballet S, Frycia A, Piron J et al (2005) Synthesis and biological evaluation of constrained analogues of the opioid peptide H-Tyr-D-Ala-Phe-Gly-NH2 using 4-amino-2-benzazepin-3-one scaffold. J Pept Res 66:222–230
Tourwe D, Verschueren K, Van Binst G et al (1992) Dermorphin sequence with high delta-affinity by fixing the Phe side-chain to trans at alpha-1. Bioorg Med Chem Lett 2:1305–1308
De Wachter R, de Graaf C, Keresztes A et al (2011) Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NH2 using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold. J Med Chem 54(19):6538–6547
Casimir JR, Tourwé D, Iterbeke K et al (2000) Efficient synthesis of (S)-4-phthalimido-1,3,4,5- tetrahydro-8-(2,6-dichlorobenzyloxy)-3-oxo-2H-2-benzazepin-2-acetic acid (Pht-Hba(2,6-Cl2-Bn)-Gly-OH). J Org Chem 65(20):6487–6492
Ruzza P, Calderan A, Donella-Deana A et al (2003) Conformational constraints of tyrosine in protein tyrosine kinase substrates: information about preferred bioactive side-chain orientation. Biopolymers 71(4):478–488
Flynn GA, Burkholder TP, Huber EW et al (1991) An acyliminium ion route to Cis and Trans “Anti” Phe-Gly dipeptide mimetics. Bioorg Med Chem Lett 1(6):309–312
Rabi-Barakay A, Ben-Ishai D (1994) Intramolecular amidoalkylation of aromatics III. Synthesis of conformationally restricted bridged peptide analogues of Phe-Gly. Tetrahedron 50(36):10771–10782
Katritzky AR, Manju K, Singh SK et al (2005) Benzotriazole mediated amino-, amido-, alkoxy- and alkylthio-alkylation. Tetrahedron 61(10):2555–2581
Ballet S, Urbanczyk-Lipkowska Z, Tourwé D (2005) Synthesis of substituted 4-amino-2-benzezepin-3-ones via N-acyliminium ion cycliations. Synlett 18:2791–2795
Ballet S, De Wachter R, Maes BUW et al (2007) Derivatization of 1-phenyl substituted 4-amino-2-benzazepin-3-ones: evaluation of Pd-catalyzed coupling reactions. Tetrahedron 63(18):3718–3727
Warshawsky AM, Flynn GA, Koehl JR et al (1996) The synthesis of aminobenzazepinones as anti-phenylalanine dipeptide mimics and their use in NEP inhibition. Bioorg Med Chem Lett 6(8):957–962
Van Rompaey K, Van den Eynde I, De Kimpe N et al (2003) A versatile synthesis of 2-substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-ones. Tetrahedron 59(24):4421–4432
Van den Eynde I, Van Rompaey K, Lazzaro F et al (2004) Solid-supported solution-phase synthesis of 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-ones. J Comb Chem 6(4):468–473
Guillemyn K, Kleczkowska P, Lesniak A et al (2015) Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist – neurokinin-1 antagonist peptidomimetics. Eur J Med Chem 92:64–77
Robl JA, Sun CQ (2001) Processes and intermediates for preparing benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP. US Patent 6,6235,922
Sedighi M, Çalimsiz S, Lipton MA (2006) An improved method for the protection of carboxylic acids as 1,1-dimethylallyl esters. J Org Chem 71(25):9517–9518
De Wachter R, Brans L, Ballet S et al (2009) Influence of ring substitution on the conformation and β-turn mimicry of 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one peptide mimetics. Tetrahedron 65(11):2266–2278
Vandormael B, De Wachter R, Martins JC et al (2011) Asymmetric synthesis and conformational analysis by NMR spectroscopy and MD of Aba- and alpha-MeAba-containing dermorphin analogues. ChemMedChem 6(11):2035–2047
Vandormael B (2011) Ph.D. thesis, Vrije Universiteit Brussel, Brussels
Tömböly C, Ballet S, Feytens D et al (2008) Endomorphin-2 with a β-turn backbone constraint retains the potent μ-opioid receptor agonist properties. J Med Chem 51(1):173–177
Van Rompaey K, Ballet S, Tömböly C et al (2006) Synthesis and evaluation of the β-turn properties of 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-ones and of their spirocyclic derivative. Eur J Med Chem 2006(13):2899–2911
Feytens D (2009) Ph.D. thesis, Vrije Universiteit Brussel, Brussels
Podlech J (2002) In: Goodman M, Felix A, Moroder L, Toniolo C (eds) Methods of organic chemistry (Houben-Weyl): synthesis of peptides and peptidomimetics. George Thieme Verlag, Stuttgart/New York, p 141
Pulka K, Feytens D, Van den Eynde I et al (2007) Synthesis of 4-amino-3-oxo-tetrahydroazepino[3,4-b]indoles: new conformationally constrained Trp analogs. Tetrahedron 63(6):1459–1466
Feytens D, De Vlaeminck M, Tourwe D (2009) A novel solid phase approach to Aia-containing peptides. J Pept Sci 15(1):16–22
Jida M, Betti C, Urbanczyk-Lipkowska Z et al (2013) Highly diastereoselective synthesis of 1-carbamoyl-4-aminoindoloazepinone derivatives via the Ugi reaction. Org Lett 15(22):5866–5869
Domling A (2006) Recent developments in isocyanide based multicomponent reactions in applied chemistry. Chem Rev 106(1):17–89
Koopmanschap G, Ruijter E, Orru RV (2014) Isocyanide-based multicomponent reactions towards cyclic constrained peptidomimetics. Beilstein J Org Chem 10:544–598
Angell YL, Burgess K (2007) Peptidomimetics via copper-catalyzed azide-alkyne cycloadditions. Chem Soc Rev 36(10):1674–1689
Pedersen DS, Abell A (2011) 1,2,3-Triazoles in peptidomimetic chemistry. Eur J Org Chem 2011(13):2399–2411
Buysse K, Farard J, Nikolaou A et al (2011) Amino triazolo diazepines (Ata) as constrained histidine mimics. Org Lett 13(24):6468–6471
Han S-Y, Kim Y-A (2004) Recent development of peptide coupling reagents in organic synthesis. Tetrahedron 60(11):2447–2467
Snieckus V, Singh SP (2014) Synthesis of aminotriazoloazepinone-containing di- and tripeptides. Synfacts 10(11):1132–1132
Hulme C, Gore V (2003) “Multi-component reactions: emerging chemistry in drug discovery” ‘from xylocain to crixivan’. Curr Med Chem 10(1):51–80
Barlow TMA, Jida M, Tourwe D et al (2014) Efficient synthesis of conformationally constrained, amino-triazoloazepinone-containing di- and tripeptides via a one-pot Ugi-Huisgen tandem reaction. Org Biomol Chem 12(36):6986–6989
Schurgers B, Brigou B, Urbanczyk-Lipkowska Z et al (2014) Synthesis of fused 3-aminoazepinones via trapping of a new class of cyclic seven-membered allenamides with furan. Org Lett 16(14):3712–3715
De Matteis V, van Delft FL, de Gelder R et al (2004) Fluorinated (hetero)cycles via ring-closing metathesis of fluoride- and trifluoromethyl-functionalized olefins. Tetrahedron Lett 45(5):959–963
Chao W, Weinreb SM (2003) The first examples of ring-closing olefin metathesis of vinyl chlorides. Org Lett 5(14):2505–2507
Kirkland TA, Grubbs RH (1997) Effects of olefin substitution on the ring-closing metathesis of dienes. J Org Chem 62(21):7310–7318
Paone DV, Shaw AW, Nguyen DN et al (2007) Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 50(23):5564–5567
Schurgers B, Van Lommen G, Verniest G (2015) Synthesis and selective N, O-functionalization of pyrazolone-fused 3-aminoazepinones. Eur J Org Chem 2015(16):3572–3576
Tanaka H, Kameyama Y, Sumida S-I et al (1991) A new short cut route to 3-norcephalosporins. Synlett 1991(12):888–890
Farina V, Kant J (1992) A new strategy for the conversion of penams into cephems via allene chemistry. Tetrahedron Lett 33(25):3559–3562
Piperno A, Rescifina A, Corsaro A et al (2007) A novel class of modified nucleosides: synthesis of alkylidene isoxazolidinyl nucleosides containing thymine. Eur J Org Chem 2007(9):1517–1521
Cheng G, Hu Y (2007) One-pot synthesis of furocoumarins through cascade addition-cyclization-oxidation. Chem Commun 31:3285–3287
Zimmermann D, Krogsgaard-Larsen P, Ehrhardt J-D et al (1998) Unambiguous synthesis of 1-methyl-3-hydroxypyrazoles. Tetrahedron 54(32):9393–9400
Cottineau B, Toto P, Marot C et al (2002) Synthesis and hypoglycemic evaluation of substituted pyrazole-4-carboxylic acids. Bioorg Med Chem Lett 12(16):2105–2108
Holzer W, Kautsch C, Laggner C et al (2004) On the tautomerism of pyrazolones: the geminal 2J[pyrazole C-4, H-3(5)] spin coupling constant as a diagnostic tool. Tetrahedron 60(32):6791–6805
Patel MV, Bell R, Majest S et al (2004) Synthesis of 4,5-diaryl-1H-pyrazole-3-ol derivatives as potential COX-2 inhibitors. J Org Chem 69(21):7058–7065
Zhang Y, Benmohamed R, Huang H et al (2013) Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J Med Chem 56(6):2665–2675
Piscopio AD, Miller JF, Koch K (1999) Ring closing metathesis in organic synthesis: evolution of a high speed, solid phase method for the preparation of β-turn mimetics. Tetrahedron 55(27):8189–8198
Hoffmann T, Waibel R, Gmeiner P (2003) A general approach to dehydro-Freidinger lactams: ex-chiral pool synthesis and spectroscopic evaluation as potential reverse turn inducers. J Org Chem 68(1):62–69
Flynn GA, Giroux EL, Dage RC (1987) An acyl-iminium ion cyclization route to a novel conformationally restricted dipeptide mimic: applications to angiotensin-converting enzyme inhibition. J Am Chem Soc 109(25):7914–7915
Thaisrivongs S, Pals DT, Harris DW et al (1986) Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo. J Med Chem 29(10):2088–2093
Montecucchi PC, de Castiglione R, Piani S et al (1981) Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei. Int J Pept Protein Res 17(3):275–283
Melchiorri P, Negri L (1996) The dermorphin peptide family. Gen Pharmacol 27:1099–1107
Ballet S, Misicka A, Kosson P et al (2008) Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem 51(8):2571–2574
Vandormael B, Fourla D-D, Gramowski-Voß A et al (2011) Superpotent [Dmt1]Dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties. J Med Chem 54(22):7848–7859
Novoa A, Van Dorpe S, Wynendaele E et al (2012) Variation of the net charge, lipophilicity, and side chain flexibility in Dmt1-DALDA: effect on opioid activity and biodistribution. J Med Chem 55(22):9549–9561
Misicka A, Lipkowski AW, Horvath R et al (1992) Topographical requirements for delta opioid ligands: common structural features of dermenkephalin and deltorphin. Life Sci 51(13):1025–1032
Schiller PW, Fundytus ME, Merovitz L et al (1999) The opioid μ agonist/δ antagonist DIPP-NH2[Ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 42(18):3520–3526
Okada Y, Tsuda Y, Fujita Y et al (2003) Unique high-affinity synthetic μ-opioid receptor agonists with central- and systemic-mediated analgesia. J Med Chem 46(15):3201–3209
Hansen D, Stapelfeld A, Savage M et al (1992) Systemic analgesic activity and delta-opioid selectivity in [2,6-dimethyl-Tyr1, D-Pen2, D-Pen5]enkephalin. J Med Chem 35:684–687
Schiller P, Nguyen T, Berezowska I et al (2000) Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur J Med Chem 35:895–901
Szeto HH, Lovelace JL, Fridland G et al (2001) In vivo pharmacokinetics of selective mu-opioid peptide agonists. J Pharmacol Exp Ther 298(1):57–61
Guillemyn K, Kleczkowska P, Novoa A et al (2012) In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera. Mol Brain 5(1):4
Zadina JE, Hackler L, Ge L-J et al (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature 386(6624):499–502
Wilkes BC, Nguyen TM, Weltrowska G et al (1998) The receptor-bound conformation of H-Tyr-Tic-(Phe-Phe)-OH-related δ-opioid antagonists contains all trans peptide bonds. J Pept Res 51(5):386–394
Lazarus LH, Bryant SD, Cooper PS et al (1998) Design of δ-opioid peptide antagonists for emerging drug applications. Drug Discov Today 3(6):284–294
Salvadori S, Attila M, Balboni G et al (1995) Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med 1(6):678–689
Van den Eynde I, Laus G, Schiller PW et al (2005) A new structural motif for μ-opioid antagonists. J Med Chem 48(10):3644–3648
Ballet S, Feytens D, Wachter RD et al (2009) Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold. Bioorg Med Chem Lett 19(2):433–437
Ballet S, Marczak ED, Feytens D et al (2010) Novel multiple opioid ligands based on 4-aminobenzazepinone (Aba), azepinoindole (Aia) and tetrahydroisoquinoline (Tic) scaffolds. Bioorg Med Chem Lett 20(5):1610–1613
King T, Gardell L, Wang R et al (2005) Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 116:276–288
Yamamoto T, Nair P, Jacobsen N et al (2010) Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines. J Med Chem 53:5491–5501
Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523–6543
Morphy R, Rankovic Z (2010) Design of multitarget ligands. In: Lead generation approaches in drug discovery. Wiley, Hoboken, pp 141–164
Fujii H (2011) Twin and triplet drugs in opioid research. Top Curr Chem 299:239–275
Kleczkowska P, Lipkowski AW, Tourwe D et al (2013) Hybrid opioid/non-opioid ligands in pain research. Curr Pharm Des 19(42):7435–7450
Lipkowski AW (1987) Cooperative reinforcement of opioid pharmacophores. Pol J Pharmacol Pharm 39:585–596
Lipkowski AW, Carr DB, Misicka A et al (1994) Biological activities of a peptide containing both casomorphin-like and substance P antagonist structural characteristics. In: Brantl V, Teschemacher H (eds) B-casomorphins and related peptides: recent developments. VCH, Weinheim, pp 113–118
Bonney IM, Foran SE, Marchand JE et al (2004) Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. Eur J Pharmacol 488(1–3):91–99
Foran SE, Carr DB, Lipkowski AW et al (2000) A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic. Proc Natl Acad Sci 97(13):7621–7626
Yamamoto T, Nair P, Davis P et al (2007) Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for δ/μ opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem 50(12):2779–2786
Yamamoto T, Nair P, Vagner J et al (2008) A structure–activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are δ/μ opioid receptor agonists and neurokinin 1 receptor antagonists. J Med Chem 51(5):1369–1376
Costantino L, Barlocco D (2012) Designed multiple ligands: basic research vs clinical outcomes. Curr Med Chem 19(20):3353–3387
Gentilucci L (2004) New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr Top Med Chem 4:19–38
Ballet S, Feytens D, Buysse K et al (2011) Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist. J Med Chem 54:2467–2476
Armour DR, Aston NM, Morriss KML et al (1997) 1,4-Benzodiazepin-2-one derived neurokinin-1 receptor antagonists. Bioorg Med Chem Lett 7(15):2037–2042
Reissmann S, Pineda F, Vietinghoff G et al (2000) Structure activity relationships for bradykinin antagonists on the inhibition of cytokine release and the release of histamine. Peptides 21(4):527–533
Bock MG, Longmore J (2000) Bradykinin antagonists: new opportunities. Curr Opin Chem Biol 4(4):401–406
Martorana PA, Kettenbach B, Breipohl G et al (1990) Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182(2):395–396
Amblard M, Daffix I, Bedos P et al (1999) Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety. J Med Chem 42(20):4185–4192
Amblard M, Daffix I, Bergé G et al (1999) Synthesis and characterization of bradykinin B2 receptor agonists containing constrained dipeptide mimics. J Med Chem 42(20):4193–4201
Amblard M, Raynal N, Averlant-Petit M-C et al (2005) Structural elucidation of the β-turn inducing (S)-[3-amino-4-oxo-2,3-dihydro-5H-benzo[b][1,4]thiazepin-5-yl] acetic acid (DBT) motif. Tetrahedron Lett 46(21):3733–3735
Ballet S, De Wachter R, Van Rompaey K et al (2007) Bradykinin analogs containing the 4-amino-2-benzazepin-3-one scaffold at the C-terminus. J Pept Sci 13(3):164–170
Janecka A, Zubrzycka M, Janecki T (2001) Somatostatin analogs. J Pept Res 58(2):91–107
Rohrer SP, Birzin ET, Mosley RT et al (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282(5389):737–740
Yang L, Berk SC, Rohrer SP et al (1998) Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci 95(18):10836–10841
Moore SB, Grant M, Rew Y et al (2005) Synthesis and biologic activity of conformationally constrained analogs of L-363,301. J Pept Res 66(6):404–422
Feytens D, Cescato R, Reubi JC et al (2007) New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold. J Med Chem 50(14):3397–3401
Feytens D, De Vlaeminck M, Cescato R et al (2009) Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities. J Med Chem 52(1):95–104
Chai SY, Fernando R, Peck G et al (2004) The angiotensin IV/AT4 receptor. Cell Mol Life Sci 61(21):2728–2737
Lukaszuk A, Demaegdt H, Szemenyei E et al (2008) Beta-homo-amino acid scan of angiotensin IV. J Med Chem 51(7):2291–2296
Lukaszuk A, Demaegdt H, Feytens D et al (2009) The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. J Med Chem 52(18):5612–5618
Nikolaou A, Van den Eynde I, Tourwe D et al (2013) [3H]IVDE77, a novel radioligand with high affinity and selectivity for the insulin-regulated aminopeptidase. Eur J Pharmacol 702(1-3):93–102
Hruby VJ, Wilkes BC, Cody WL et al (1984) Melanotropins: structural, conformational and biological considerations in the development of superpotent and superprolonged analogues. Pept Protein Rev 3:1–64
Cone RD, Lu D, Koppula S et al (1996) The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 51:287–317
Fan W, Boston BA, Kesterson RA et al (1997) Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385(6612):165–168
Huszar D, Lynch CA, Fairchild-Huntress V et al (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88(1):131–141
Al-Obeidi F, Castrucci AM, Hadley ME et al (1989) Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem 32(12):2555–2561
Al-Obeidi F, Hadley ME, Pettitt BM et al (1989) Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamic simulations. J Am Chem Soc 111(9):3413–3416
Ballet S, Mayorov AV, Cai M et al (2007) Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold. Bioorg Med Chem Lett 17(9):2492–2498
Proneth B, Pogozheva ID, Portillo FP et al (2008) Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity. J Med Chem 51(18):5585–5593
Holder JR, Bauzo RM, Xiang Z et al (2002) Structure−activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors: part 2 modifications at the Phe position. J Med Chem 45(14):3073–3081
Van der Poorten O, Feher K, Buysse K et al (2015) Azepinone-containing tetrapeptide analogues of melanotropin lead to selective hMC4R agonists and hMC5R antagonist (2015) ACS Med Chem Lett 6(2):192–197
Pogozheva ID, Chai BX, Lomize AL et al (2005) Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists. Biochemistry 44(34):11329–11341
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ballet, S., Guillemyn, K., Van der Poorten, O., Schurgers, B., Verniest, G., Tourwé, D. (2015). Azepinone-Constrained Amino Acids in Peptide and Peptidomimetic Design. In: Lubell, W. (eds) Peptidomimetics I. Topics in Heterocyclic Chemistry, vol 48. Springer, Cham. https://doi.org/10.1007/7081_2015_161
Download citation
DOI: https://doi.org/10.1007/7081_2015_161
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-49117-2
Online ISBN: 978-3-319-49119-6
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)